<code id='F533537C0D'></code><style id='F533537C0D'></style>
      • <acronym id='F533537C0D'></acronym>
      <center id='F533537C0D'><center id='F533537C0D'><tfoot id='F533537C0D'></tfoot></center><abbr id='F533537C0D'><dir id='F533537C0D'><tfoot id='F533537C0D'></tfoot><noframes id='F533537C0D'>
      • <optgroup id='F533537C0D'><strike id='F533537C0D'><sup id='F533537C0D'></sup></strike><code id='F533537C0D'></code></optgroup>
        5. <b id='F533537C0D'><label id='F533537C0D'><select id='F533537C0D'><dt id='F533537C0D'><span id='F533537C0D'></span></dt></select></label></b><u id='F533537C0D'></u>
          <i id='F533537C0D'><strike id='F533537C0D'><tt id='F533537C0D'><pre id='F533537C0D'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-30 04:14:24 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：225
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Pfizer's Covid pill remains 89% effective in final analysis, company says
                                
                            
          Next article：  
                                      
                                          BioMarin wins approval for gene therapy to treat hemophilia A
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles